Susan McLaughlin

972 total citations
33 papers, 707 citations indexed

About

Susan McLaughlin is a scholar working on Finance, Oncology and Molecular Biology. According to data from OpenAlex, Susan McLaughlin has authored 33 papers receiving a total of 707 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Finance, 9 papers in Oncology and 5 papers in Molecular Biology. Recurrent topics in Susan McLaughlin's work include Banking stability, regulation, efficiency (9 papers), Credit Risk and Financial Regulations (3 papers) and Childhood Cancer Survivors' Quality of Life (2 papers). Susan McLaughlin is often cited by papers focused on Banking stability, regulation, efficiency (9 papers), Credit Risk and Financial Regulations (3 papers) and Childhood Cancer Survivors' Quality of Life (2 papers). Susan McLaughlin collaborates with scholars based in United States, United Kingdom and Japan. Susan McLaughlin's co-authors include André Rogatko, Susan Hunter, Paul Sabatier, Mary Beard, Margaret von Mehren, Louis M. Weiner, Jeffrey Schlom, Philip M. Arlen, Harry S. Cooper and Antoine Martin and has published in prestigious journals such as Journal of Clinical Oncology, Scientific Reports and Clinical Chemistry.

In The Last Decade

Susan McLaughlin

26 papers receiving 677 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Susan McLaughlin United States 11 317 237 186 96 67 33 707
Mark Napier United Kingdom 16 287 0.9× 61 0.3× 260 1.4× 36 0.4× 117 1.7× 46 962
Hanwei Huang China 17 156 0.5× 69 0.3× 302 1.6× 38 0.4× 62 0.9× 50 931
Mark Schneider United States 15 143 0.5× 213 0.9× 187 1.0× 21 0.2× 20 0.3× 39 1.1k
Michael Cuddy United States 20 306 1.0× 176 0.7× 816 4.4× 25 0.3× 25 0.4× 44 1.3k
Hideki Kanda Japan 15 114 0.4× 22 0.1× 169 0.9× 50 0.5× 214 3.2× 73 693
Luz Muñoz Spain 15 191 0.6× 141 0.6× 140 0.8× 7 0.1× 52 0.8× 37 799
Peter Diamond Australia 20 409 1.3× 198 0.8× 616 3.3× 10 0.1× 73 1.1× 38 1.3k
Joanna Węgrzyn Poland 14 415 1.3× 320 1.4× 676 3.6× 10 0.1× 70 1.0× 39 1.3k
Helga Kristjánsdóttir Iceland 18 241 0.8× 750 3.2× 94 0.5× 55 0.6× 15 0.2× 50 1.3k
Martin Jones Canada 13 170 0.5× 14 0.1× 201 1.1× 58 0.6× 119 1.8× 49 639

Countries citing papers authored by Susan McLaughlin

Since Specialization
Citations

This map shows the geographic impact of Susan McLaughlin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Susan McLaughlin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Susan McLaughlin more than expected).

Fields of papers citing papers by Susan McLaughlin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Susan McLaughlin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Susan McLaughlin. The network helps show where Susan McLaughlin may publish in the future.

Co-authorship network of co-authors of Susan McLaughlin

This figure shows the co-authorship network connecting the top 25 collaborators of Susan McLaughlin. A scholar is included among the top collaborators of Susan McLaughlin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Susan McLaughlin. Susan McLaughlin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Xu, Yvonne Yiru, Aleksandr Y. Aravkin, Peng Zheng, et al.. (2025). A burden of proof study of the effects of exposure to high fasting plasma glucose on the risk of seven types of cancer. Scientific Reports. 15(1). 28859–28859.
2.
Burkart, Katrin, Caihua Liang, Quinn Rafferty, et al.. (2025). Respiratory syncytial virus-attributable hospitalizations among adults in high- and middle-income countries: application of the Global Burden of Disease framework. EClinicalMedicine. 85. 103292–103292. 3 indexed citations
3.
Anderson, Tara, Gary Mitchell, Gillian Prue, Susan McLaughlin, & Lisa Graham‐Wisener. (2025). The psychosocial impact of pancreatic cancer on caregivers: a scoping review. BMC Cancer. 25(1). 511–511. 2 indexed citations
4.
5.
Anderson, Tara, Gillian Prue, Lisa Graham‐Wisener, Susan McLaughlin, & Gary Mitchell. (2024). Exploring the supportive care needs of families affected by pancreatic cancer: a mixed-methods study protocol. BMC Cancer. 24(1). 1540–1540.
6.
McLaughlin, Susan. (2017). Foreign Exchange Liquidity in the Americas. SSRN Electronic Journal. 7 indexed citations
7.
Martin, Antoine & Susan McLaughlin. (2015). Financial Innovation: The Origins of the Tri-Party Repo Market. Liberty Street Economics. 1 indexed citations
8.
Martin, Antoine, et al.. (2015). THE RISK OF FIRE SALES IN THE TRI‐PARTY REPO MARKET. Contemporary Economic Policy. 34(3). 513–530. 4 indexed citations
9.
McLaughlin, Susan, et al.. (2013). Unlocking Company Law. Nottingham Trent University's Institutional Repository (Nottingham Trent Repository).
10.
Copeland, Adam, Darrell Duffie, Antoine Martin, & Susan McLaughlin. (2012). Key Mechanics of the U.S. Tri-Party Repo Market. Federal Reserve Bank of New York Economic policy review. 17. 52 indexed citations
11.
Copeland, Adam, Darrell Duffie, Antoine Martin, & Susan McLaughlin. (2012). Explaining the U.S. tri-party repo market. RePEc: Research Papers in Economics. 18. 17–28. 6 indexed citations
12.
Sacks, David B., Richard M. Bergenstal, & Susan McLaughlin. (2010). Point: The Reporting of Estimated Glucose with Hemoglobin A1c. Clinical Chemistry. 56(4). 545–546. 7 indexed citations
13.
Denlinger, Crystal S., Rebecca Blanchard, Lu Xu, et al.. (2009). Pharmacokinetic analysis of irinotecan plus bevacizumab in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 65(1). 97–105. 21 indexed citations
14.
Cohen, Steven J., Paul F. Engstrom, Nancy Lewis, et al.. (2008). Phase I Study of Capecitabine and Oxaliplatin in Combination With the Proteasome Inhibitor Bortezomib in Patients With Advanced Solid Tumors. American Journal of Clinical Oncology. 31(1). 1–5. 12 indexed citations
15.
Henry, Leonard R., Melvyn Goldberg, Walter J. Scott, et al.. (2006). Induction Cisplatin and Paclitaxel Followed by Combination Chemoradiotherapy with 5-Fluorouracil, Cisplatin, and Paclitaxel Before Resection in Localized Esophageal Cancer: A Phase II Report. Annals of Surgical Oncology. 13(2). 214–220. 29 indexed citations
16.
Mehren, Margaret von, S P Balcerzak, Andrew S. Kraft, et al.. (2004). Phase II Trial of Dolastatin‐10, a Novel Anti‐Tubulin Agent, in Metastatic Soft Tissue Sarcomas. Sarcoma. 8(4). 107–111. 28 indexed citations
17.
Mehren, Margaret von, Philip M. Arlen, James L. Gulley, et al.. (2001). The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma.. PubMed. 7(5). 1181–91. 138 indexed citations
18.
McLaughlin, Susan, et al.. (1996). Environmental accounting and EMSs. 6(2). 13–21. 3 indexed citations
19.
McLaughlin, Susan. (1995). The Impact of Interstate Banking and Branching Reform: Evidence from the States. SSRN Electronic Journal. 1. 15 indexed citations
20.
Sabatier, Paul, Susan Hunter, & Susan McLaughlin. (1987). The Devil Shift: Perceptions and Misperceptions of Opponents. The Western Political Quarterly. 40(3). 449–449. 86 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mark Napier Breakdown of academic impact, for papers by Hanwei Huang Breakdown of academic impact, for papers by Mark Schneider Breakdown of academic impact, for papers by Michael Cuddy Breakdown of academic impact, for papers by Hideki Kanda Breakdown of academic impact, for papers by Luz Muñoz Breakdown of academic impact, for papers by Peter Diamond Breakdown of academic impact, for papers by Joanna Węgrzyn Breakdown of academic impact, for papers by Helga Kristjánsdóttir Breakdown of academic impact, for papers by Martin Jones
Rankless by CCL
2026